Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer-Reference-Cited by-同舟云学术

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

Published:2020-04-01 Issue:4 Volume:6 Page:505
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Woodward Wendy A.¹,Barlow William E.²,Jagsi Reshma³,Buchholz Thomas A.¹,Shak Steven⁴,Baehner Frederick⁴⁵,Whelan Timothy J.⁶,Davidson Nancy E.⁷⁸,Ingle James N.⁹,King Tari A.¹⁰,Ravdin Peter M.¹¹,Osborne C. Kent¹²,Tripathy Debasish¹³,Livingston Robert B.¹⁴,Gralow Julie R.¹⁵,Hortobagyi Gabriel N.¹³,Hayes Daniel F.¹⁶,Albain Kathy S.¹⁷

Affiliation:

1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston

2. Cancer Research and Biostatics, Seattle, Washington

3. Department of Radiation Oncology, University of Michigan, Ann Arbor

4. Department of Pathology, Genomic Health Inc, Redwood City, California

5. Department of Pathology, University of California San Francisco, San Francisco

6. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

7. Division of Medical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

8. Division of Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington

9. Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota

10. Department of Surgery, Dana-Farber Cancer Institute, Boston, Massachusetts

11. Department of Medicine, Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio

12. Department of Medicine, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas

13. Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston

14. Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson

15. Department of Medicine, Division of Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle

16. Department of Internal Medicine, University of Michigan, Ann Arbor

17. Department of Medicine, Division of Hematology/Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2758265/jamaoncology_woodward_2020_oi_190100.pdf

Reference15 articles.

1. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.;Drukker;Breast Cancer Res Treat,2014

2. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.;Paik;N Engl J Med,2004

3. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.;Scott;Lancet Oncol,2017

4. Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.;Zhang;Nat Commun,2016

5. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.;Albain;Lancet Oncol,2010

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature;Journal of Clinical Oncology;2024-04-01

2. 21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery;The Breast;2024-04

3. Correlation between postoperative treatment selection and prognosis determined using the Oncotype DX® test data: a retrospective multicenter study in Japan;Breast Cancer;2024-03-07

4. Genomic Testing to Guide Local Therapy Decisions in Hormone Receptor-Positive Breast Cancer;Current Breast Cancer Reports;2024-03-07

5. Increased PI3K pathway activity is associated with recurrent breast cancer in patients with low and intermediate 21-gene recurrence score;Journal of Clinical Pathology;2024-02-21